Literature DB >> 15067175

The significance of angiogenesis in malignant pheochromocytomas.

Patrick P G M Rooijens1, Ronald R de Krijger, H Jaap Bonjer, Frieda van der Ham, Alex L Nigg, Hajo A Bruining, Steven W J Lamberts, Erwin van der Harst.   

Abstract

The purpose of this study was to investigate tumor angiogenesis in a series of benign and malignant pheochromocytomas and to determine whether there is a correlation between angiogenesis and the presence of distant metastases. In this study, the CD31 monoclonal antibody was selected to measure intratumoral microvessel density. Nineteen patients with malignant pheochromocytomas and nineteen patients with benign pheochromocytomas who underwent operation were studied. In order to quantify intratumoral microvessel density, the total number of pixels of CD31-positive reactivity was assessed and expressed as a percentage of the total tissue area in the analyzed field. Analysis of variance revealed a statistically significant correlation between malignancy and intratumoral microvessel density (p = 0.0009). Although there was a considerable variability in the intratumoral microvessel density from tumor to tumor within both the benign and the malignant group, a percentage of more than 28.5% anti-CD31 stained area was found only in malignant tumors. In conclusion, this study shows that the mean intratumoral microvessel density in malignant pheochromocytomas is increased approximately twofold as compared with benign tumors. However, the clinical significance of this prognostic marker is rather weak, because only 4 of the 19 malignant pheochromocytomas had microvessel density higher than this threshold of 28.5%.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067175     DOI: 10.1385/ep:15:1:39

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  27 in total

Review 1.  Tumoral vascularity as a prognostic factor in cancer.

Authors:  N Weidner; J Folkman
Journal:  Important Adv Oncol       Date:  1996

Review 2.  Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition.

Authors:  J A Nagy; L F Brown; D R Senger; N Lanir; L Van de Water; A M Dvorak; H F Dvorak
Journal:  Biochim Biophys Acta       Date:  1989-02

Review 3.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

4.  Tumour angiogenesis and Ki-67 expression in phaeochromocytoma.

Authors:  H Ohji; I Sasagawa; O Iciyanagi; Y Suzuki; T Nakada
Journal:  BJU Int       Date:  2001-03       Impact factor: 5.588

5.  Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?

Authors:  E van der Harst; H A Bruining; H Jaap Bonjer; F van der Ham; W N Dinjens; S W Lamberts; W W de Herder; J W Koper; T Stijnen; C Proye; M Lecomte-Houcke; F T Bosman; R R de Krijger
Journal:  J Pathol       Date:  2000-06       Impact factor: 7.996

6.  Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma.

Authors:  N Weidner; P R Carroll; J Flax; W Blumenfeld; J Folkman
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 7.  Pheochromocytoma. Update on diagnosis, localization, and management.

Authors:  S S Werbel; K P Ober
Journal:  Med Clin North Am       Date:  1995-01       Impact factor: 5.456

8.  "The" pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist?

Authors:  C A Proye; M Vix; S Jansson; L E Tisell; H Dralle; W Hiller
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

9.  Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease.

Authors:  D Olivarez; T Ulbright; W DeRiese; R Foster; T Reister; L Einhorn; G Sledge
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

Review 10.  Tumor angiogenesis and the role of vascular cell integrin alphavbeta3.

Authors:  J A Varner; D A Cheresh
Journal:  Important Adv Oncol       Date:  1996
View more
  6 in total

1.  Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

Authors:  Judith Favier; Peter Igaz; Nelly Burnichon; Laurence Amar; Rossella Libé; Cécile Badoual; Frédérique Tissier; Jérôme Bertherat; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 2.  Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Authors:  Aoife J Lowery; Siun Walsh; Enda W McDermott; Ruth S Prichard
Journal:  Oncologist       Date:  2013-04-10

3.  Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma.

Authors:  Carla Vaz Ferreira; Débora Rodrigues Siqueira; Mírian Romitti; Lucieli Ceolin; Beatriz Assis Brasil; Luise Meurer; Clarissa Capp; Ana Luiza Maia
Journal:  Int J Mol Sci       Date:  2014-03-26       Impact factor: 5.923

4.  Study of microvessel density and the expression of vascular endothelial growth factors in adrenal gland pheochromocytomas.

Authors:  Magdalena Białas; Grzegorz Dyduch; Joanna Dudała; Monika Bereza-Buziak; Alicja Hubalewska-Dydejczyk; Andrzej Budzyński; Krzysztof Okoń
Journal:  Int J Endocrinol       Date:  2014-09-03       Impact factor: 3.257

5.  Vascular pattern analysis for the prediction of clinical behaviour in pheochromocytomas and paragangliomas.

Authors:  Lindsey Oudijk; Francien van Nederveen; Cécile Badoual; Frédérique Tissier; Arthur S Tischler; Marcel Smid; José Gaal; Charlotte Lepoutre-Lussey; Anne-Paule Gimenez-Roqueplo; Winand N M Dinjens; Esther Korpershoek; Ronald de Krijger; Judith Favier
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  Targeting heat shock protein 90 for the treatment of malignant pheochromocytoma.

Authors:  Alessio Giubellino; Carole Sourbier; Min-Jung Lee; Brad Scroggins; Petra Bullova; Michael Landau; Weiwen Ying; Len Neckers; Jane B Trepel; Karel Pacak
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.